LBLaurie K. Barker

Laurie K. Barker

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Laurie K. Barker has a total of 43 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Estimated Hepatitis C Prevalence and Viral Clearance Using Residual Sera From a Large Commercial Laboratory: November 2023–September 2024

    by Megan G Hofmeister, Hasan Symum, Brooke E Swanson, Laurie K Barker, Yuna Zhong, Harvey W Kaufman, William W Thompson, William A Meyer, Neil Gupta

    Background: Hepatitis C is a public health threat with national elimination targets, yet prevalence is challenging to measure. We utilized a novel approach to estimate hepatitis C prevalence among adults using residual sera from a large commercial laboratory. Methods: We conducted a cross-sectional study in 50 states and the District of Columbia using a convenience sample of residual serum specimens (n = 81 483) among routine clinical specimens from adults aged 18–≤75 years. We randomly sampled within 2 age groups (18–≤49 years and 50–≤75 years) during November 2023–September 2024. Specimens were tested for hepatitis C virus (HCV) antibodies; reactive or equivocal results were reflexed to HCV ribonucleic acid (RNA) testing. We performed nested raking on the age–sex distribution of the United States. Results: Among adults aged 18–≤75 years, we estimated that the HCV antibody prevalence was 2.9% (95% CI, 2.8%–3.0%), corresponding to 6 887 000 (95% CI, 6 622 000–7 166 000) persons ever infected, and the HCV RNA prevalence was 0.7% (95% CI, .7%–.8%), corresponding to 1 698 000 (95% CI, 1 554 000–1 845 000) persons currently infected. Viral clearance was lower among younger adults (63.8% [95% CI, 60.6%–66.9%]) than older adults (81.1% [95% CI, 78.9%–83.3%]). Conclusions: In this analysis of residual sera from a commercial laboratory, we estimated that approximately 1.70 million adults were diagnosed with HCV infection during November 2023–September 2024. Although underlying selection bias limits generalizability to the US population, the substantial burden estimated after a decade of available curative treatment underscores the need for concerted nationwide hepatitis C elimination efforts.


  • Open Access

    Hepatitis C Surveillance in the United States: Past, Present, and Future

    by Laurie K. Barker, Mona Doshani, Ruth B. Jiles, Eyasu Teshale

    Data from 3 US public health surveillance systems indicate that an estimated 67 400 people acquired hepatitis C virus infections in 2022, 2.2 million adults had hepatitis C during January 2017–March 2020, and 12 717 people died in 2022 from hepatitis C–related causes, despite the availability of curative treatment since 2013. The 3 surveillance systems that provided these data—the National Notifiable Diseases Surveillance System, the National Health and Nutrition Examination Survey, and the National Vital Statistics System—were selected to monitor progress toward elimination of hepatitis C as a public health threat in the United States by 2030. However, some limitations of these surveillance systems compel the use of additional data sources with more timely information for the general population and for populations with higher incidence, prevalence, or mortality of hepatitis C, such as those experiencing homelessness, incarceration, or injection drug use. Commercial laboratories, health systems, and programs serving these populations could provide such data. This topical review of hepatitis C surveillance describes the history, long-term trends, and recent investments in public health surveillance for hepatitis C. Strengthening and modernizing the hepatitis C surveillance workforce and systems, improving data system interoperability, linking complementary data sources, and leveraging multiple data systems can aid in the measurement of public health efforts to meet hepatitis C elimination goals.


  • Disparities in hepatitis C among people aged 12–59 with no history of injection drug use, United States, January 2013–March 2020

    by Kathleen N. Ly, Laurie K. Barker, Greta Kilmer, Jaimie Z. Shing, Ruth B. Jiles, Eyasu Teshale

    Background and Aims: In the United States, hepatitis C virus (HCV) infection occurs primarily through injection drug use (IDU), but transmission also occurs through other ways. This study examined HCV prevalence and disparities among US residents aged 12–59 years with no IDU history.Methods: We analysed 2013‐March 2020 National Health and Nutrition Examination Survey data to calculate the HCV prevalence among people with no drug use history and only a non‐IDU history, collectively referred to as no IDU history. These estimates were compared to those with an IDU history and stratified by sociodemographic and hepatitis A and hepatitis B serologic characteristics.Results: The current HCV infection prevalence among people aged 12–59 was .7% overall, and specifically 17.2% among people with an IDU history, .9% among people with a non‐IDU history and .2% among people with no drug use history. These rates represented 1.4 million people with current HCV infection, of whom, 730 000 had an IDU history, 262 000 had a non‐IDU history and 309 000 had no drug use history. Among people with no drug use history, current HCV infection prevalence was higher for people born during 1954–1965 versus after 1965, had completed high school or less versus at least some college and had past/present hepatitis B versus vaccinated for hepatitis B.Conclusion: While the HCV infection burden was highest among people with an IDU history, we found a sizeable burden among people without such a history. These findings support policies and practices aimed at addressing disparities among people needing treatment.


  • Estimating the Prevalence of Injection Drug Use Among Acute Hepatitis C Cases From a National Surveillance System: Application of Random Forest-Based Multiple Imputation

    by Shaoman Msph Yin, Kathleen N. Ly, Laurie K. Msph Barker, Danae Bixler, Nicola D. Thompson, Neil Gupta

    Background: Injection drug use (IDU) is a major contributor to the syndemic of viral hepatitis, human immunodeficiency virus, and drug overdose. However, information on IDU is frequently missing in national viral hepatitis surveillance data, which limits our understanding of the full extent of IDU-associated infections. Multiple imputation by chained equations (MICE) has become a popular approach to address missing data, but its application for IDU imputation is less studied. Methods: Using the 2019-2021 National Notifiable Diseases Surveillance System acute hepatitis C case data and publicly available county-level measures, we evaluated listwise deletion (LD) and 3 models imputing missing IDU data through MICE: parametric logistic regression, semi-parametric predictive mean matching (PMM), and nonparametric random forest (RF) (both standard RF [sRF] and fast implementation of RF [fRF]). Results: The estimated IDU prevalence among acute hepatitis C cases increased from 63.5% by LD to 65.1% by logistic regression, 66.9% by PMM, 76.0% by sRF, and 85.1% by fRF. Evaluation studies showed that RF-based MICE imputation, especially fRF, has the highest accuracy (as measured by smallest raw bias, percent bias, and root mean square error) and highest efficiency (as measured by smallest 95% confidence interval width) compared to LD and other models. Sensitivity analyses indicated that fRF remained robust when data were missing not at random. Conclusion: Our analysis suggested that RF-based MICE imputation, especially fRF, could be a valuable approach for addressing missing IDU data in the context of population-based surveillance systems like National Notifiable Diseases Surveillance System. The inclusion of imputed IDU data may enhance the effectiveness of future surveillance and prevention efforts for the IDU-driven syndemic.


  • Estimating hepatitis C prevalence in the United States, 2017–2020

    by Eric W. Hall, Heather Bradley, Laurie K. Barker, Karon C. Lewis, Jalissa Shealey, Eduardo Valverde, Patrick Sullivan, Neil Gupta, Megan G. Hofmeister

    Background & Aims: The National Health and Nutrition Examination Survey (NHANES) underestimates the true prevalence of hepatitis C virus (HCV) infection. By accounting for populations inadequately represented in NHANES, we created two models to estimate the national hepatitis C prevalence among US adults during 2017–2020. Approach & Results: The first approach (NHANES+) replicated previous methodology by supplementing hepatitis C prevalence estimates among the US noninstitutionalized civilian population with a literature review and meta-analysis of hepatitis C prevalence among populations not included in the NHANES sampling frame. In the second approach (persons who inject drugs [PWID] adjustment), we developed a model to account for underrepresentation of PWID in NHANES by incorporating the estimated number of adult PWID in the United States and applying PWID-specific hepatitis C prevalence estimates. Using the NHANES+ model, we estimated HCV RNA prevalence of 1.0% (95% confidence interval [CI]: 0.5%-1.4%) among US adults in 2017-2020, corresponding to 2,463,700 (95% CI: 1,321,700-3,629,400) current HCV infections. Using the PWID adjustment model, we estimated HCV RNA prevalence of 1.6% (95% CI: 0.9%-2.2%), corresponding to 4,043,200 (95% CI: 2,401,800-5,607,100) current HCV infections. Conclusions: Despite years of an effective cure, estimated prevalence of hepatitis C in 2017–2020 remains unchanged from 2013–2016 when using comparable methodology. When accounting for increased injection drug use, estimated prevalence of hepatitis C is substantially higher than previously reported. National action is urgently needed to expand testing, increase access to treatment, and improve surveillance, especially among medically underserved populations, to support hepatitis C elimination goals. Export


  • Prevalence and awareness of Hepatitis B virus infection in the United States: January 2017 - March 2020

    by Danae Bixler, Laurie Barker, Karon Lewis, Lauren Peretz, Eyasu Teshale

    Background: Prevalence and awareness of HBV infection are important national indicators of progress toward hepatitis B elimination. Methods: National Health and Nutrition Examination Survey participants were examined for laboratory evidence of HBV infection (positive antibody to HBcAg and HBsAg), and interviewed to determine awareness of HBV infection. Estimates of HBV infection prevalence and awareness were calculated for the US population. Findings: Among National Health and Nutrition Examination Survey participants aged 6 years and older evaluated from January 2017 through March 2020, an estimated 0.2% had HBV infection; of these 50% were aware of their infection.


  • Prevalence of past‐year dental visit among US adults, 1999–2010: comparison of trends and estimates between the Behavioral Risk Factor Surveillance System and three national surveys

    by Mei Lin, Chien‐Hsun Li, Liang Wei, Shillpa Naavaal, Shellie Kolavic Gray, Michael C. Manz, Laurie Barker

    Objectives: To compare estimated prevalence of past‐year dental visit (PPYDV) among US adults aged ≥18 years from the Behavioral Risk Factor Surveillance System (BRFSS) to estimates from the Medical Expenditure Panel Survey (MEPS), National Health Interview Survey (NHIS), and National Health and Nutrition Examination Survey (NHANES).Methods: We estimated PPYDV adjusted for covariates (age, race/ethnicity, education level, poverty status, edentulism) using BRFSS, MEPS, and NHIS 1999–2010, and NHANES 1999–2004. We tested trend in overall PPYDV for BRFSS, MEPS, and NHIS from 1999–2010. For 2002 and 2010, we calculated absolute differences (AD) and 95% confidence intervals (CI) in PPYDV between BRFSS and each of the other surveys overall and among subpopulations defined by covariates. We pooled NHANES 1999–2004 data for comparison with BRFSS 2002.Results: From 1999 to 2010, BRFSS (68.5% vs. 67.5%), MEPS (43.5% vs. 39.7%), and NHIS (63.3% vs. 59.7%) showed small but significant decreases in overall PPYDV. In 2002, estimates for overall PPYDV were highest for BRFSS (70.0%) and lowest for MEPS (43.9%) with estimates for NHIS (61.5%) and NHANES (1999–2004: 58.1%) in between; the largest AD (26.2%, 95% CI: 25.0%–27.3%) was between BRFSS and MEPS. ADs were consistent in 2002 and 2010, overall and by covariates, except among edentate persons, where PPYDV estimates from BRFSS and NHIS were similar.Conclusions: Estimates of PPYDV from BRFSS were notably higher than estimates from MEPS, NHIS, or NHANES except among the edentate. Trends in PPYDV over time, however, were consistent across all surveys.


  • The effect of health and dental insurance on US children's dental care utilization for urgent and non‐urgent dental problems ‐ 2008

    by Shillpa Naavaal, Laurie K. Barker, Susan O. Griffin

    Objective: We examined the association between utilization of care for a dental problem (utilization‐DP) and parent‐reported dental problem (DP) urgency among children with DP by type of health care insurance coverage.Methods: We used weighted 2008 National Health Interview Survey data from 2,834 children, aged 2–17 years with at least one DP within the 6 months preceding survey. Explanatory variables were selected based on Andersen's model of healthcare utilization. Need was considered urgent if DP included toothache, bleeding gums, broken or missing teeth, broken or missing filling, or decayed teeth and otherwise as non‐urgent. The primary enabling variable, insurance, had four categories: none, private health no dental coverage (PHND), private health and dental (PHD), or Medicaid/State Children's Health Insurance Program (SCHIP). Predisposing variables included sociodemographic characteristics. We used bivariate and multivariate analyses to identify explanatory variables’ association with utilization‐DP. Using logistic regression, we obtained adjusted estimates of utilization‐DP by urgency for each insurance category.Results: In bivariate analyses, utilization‐DP was associated with both insurance and urgency. In multivariate analyses, the difference in percent utilizing care for an urgent versus non‐urgent DP among children covered by Medicaid/SCHIP was 32 percentage points; PHD, 25 percentage points; PHND, 12 percentage points; and no insurance, 14 percentage points. The difference in utilization by DP urgency was higher for children with Medicaid/SCHIP compared with either PHND or uninsured children.Conclusion: Expansion of Medicaid/SCHIP may permit children to receive care for urgent DPs who otherwise may not, due to lack of dental insurance.


    • 1 April 2007
      • No. 248,p. 1-92

    Trends in oral health status: United States, 1988-1994 and 1999-2004.

    by Bruce A Dye, Sylvia Tan, Vincent Smith, Brenda G Lewis, Laurie K Barker, Gina Thornton-Evans, Paul I Eke, Eugenio D Beltrán-Aguilar, Alice M Horowitz, Chien-Hsun Li

    This report presents national estimates and trends for a variety of oral health status measures for persons aged 2 years and older by sociodemographic and smoking status since the late 1980s in the United States. Data from the third National Health and Nutrition Examination Survey (NHANES III), 1988-1994 and from the NHANES 1999-2004 were used. These data sources were designed to provide information on the health and nutritional status of the civilian noninstitutionalized population in the United States. Information from oral health examination methods common to both survey periods were used to present prevalence estimates and for trend analyses. Statistical significance of differences between common estimates from each survey period was evaluated using two-sided t-tests. This report provides mean, percentile values, and standard errors for dental caries, dental sealants, incisal trauma, periodontal health, dental visits, perception of oral health status, tooth retention, and edentulism. Additional estimates for monitoring progress toward the Healthy People 2010 oral health objectives using NHANES source data are presented as well. For most Americans, oral health status has improved between 1988-1994 and 1999-2004. For seniors, edentulism and periodontitis has declined; for adults, improvements were seen in dental caries prevalence, tooth retention, and periodontal health; for adolescents and youths, dental sealant prevalence has increased and dental caries have decreased; however, for youths aged 2-5 years, dental caries in primary teeth has increased.